ACTRN12621000038897已完成未知
The effects of Lutein/Zeaxanthin supplementation on cognitive function in adults with self-reported mild cognitive complaints: a randomised, double-blind, placebo-controlled study
Clinical Research Australia0 个研究点目标入组 96 人开始时间: 2021年1月18日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 96
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 40 Years 至 75 Years（—）
- 性别
- All
入选标准
- •1. Healthy adults (male and female) between 40 and 75 years
- •2. Residing in independent living accommodation
- •3. Subjective report of memory or attention problems by answering ‘yes’ to the following question: Do you have problems with your memory, attention, or concentration?
- •4. Non-smoker
- •5. BMI between 18 and 35 kg/m2
- •6. No plan to commence new treatments over the study period
- •7. Understand, willing and able to comply with all study procedures
- •8. Willing to provide a personally signed and dated informed consent form detailing all pertinent aspects of the trial.
排除标准
- •1. Diagnosis of dementia based on the revised National Institute on Aging-Alzheimer’s Association (NIA/AA) criteria
- •2. A score below the 5th percentile for age, education, and gender on the Telephone Interview for Cognitive Status (TICS-M)
- •3. Suffering from recently diagnosed or unmanaged medical conditions including but not limited to: diabetes, hyper/hypotension, cardiovascular disease, gastrointestinal disease requiring regular use of medications, gallbladder disease/gallstones/biliary disease, autoimmune disease, endocrine disease, acute or chronic pain condition
- •4. Diagnosis of medical or psychiatric conditions including but not limited to: psychiatric disorder (other than mild-to-moderate depression or anxiety), neurological disease (Parkinson’s, Alzheimer’s disease, intracranial haemorrhage, head or brain injury), or cancer/malignancy
- •5. History of stroke or seizures or head injury (with loss of consciousness).
- •6. Regular medication intake including but not limited to anticholinergics, acetylcholinesterase inhibitors, or steroid medications.
- •7. Change in medication in the last 3 months or expectation to change during the study duration
- •8. Current nutrient deficiencies including low iron or vitamin B12 concentrations
- •9. Taking vitamins or herbal supplements that are reasonably expected to influence study measures.
- •10. Current or 12-month history of illicit drug abuse
- •11. Alcohol intake greater than 14 standard drinks per week
- •12. Any significant surgeries over the last year
研究者
相似试验
已完成
不适用
Effect of Lutein, Zeaxanthin supplements on human.Healthy peopleJPRN-UMIN000025699aboratory of Systematic Forest and Forest Products Science, Faculty of Agriculture, Kyushu University40
已完成
不适用
Effects of Lutein and Zeaxanthin Supplementation on Early Age-related Macular DegenerationAge-related Macular DegenerationNCT01528605Peking University168
Unknown
1 期
Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular DegenerationAge-related Macular DegenerationNCT01048476Peking University120
进行中（未招募）
Unknown
Effects of lutein/ zeaxanthin on eye health, eye strain, sleep quality, and attention in high electronic screen usersACTRN12623000427673Clinical Research Australia70
已完成
1 期
Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60Macular DegenerationNCT00121589National Eye Institute (NEI)40